Articles

Affichage des articles associés au libellé Scientist I/II

Scientist I/II, Analytical Development

Job title: Scientist I/II, Analytical Development Company: Biogen Job description : Job Description About This Role The successful candidate will join the Bioassay Development and Analytics (BioDnA) Group in the Analytical Development Department and be responsible for development of analytical methods for characterization of Protein and AAV gene therapy products to support process development, product characterization, and manufacturing activities. What You’ll Do Design, perform, and analyze experiments for multiple projects. Develop and qualify potency assays, including cell-based assays Contribute to new technology implementation, including next generation sequencing (NGS) for gene therapy applications. Liaise between stakeholders to maintain effective communication and ensure project progress. Prepare technical documents/reports and present scientific data at internal and external meetings/conferences. Work both independently and as part of a team. Who You Are Hig...

Scientist I/II, Immune Oncology & In Vivo Pharmacology

Job title: Scientist I/II, Immune Oncology & In Vivo Pharmacology Company: NGM Biopharmaceuticals Job description : NGM Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to build a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine that has a track record of generating one new IND candidate per year. NGM’s current pipeline of clinical-stage programs consists of five drug candidates targeting liver and metabolic diseases, retinal diseases and cancer. The most advanced drug candidate, aldafermin (NGM282), is in Phase 2b clinical studies in non-alcoholic steatohepatitis (NASH) and is wholly-owned by NGM. Another drug candidate, NGM621, is in a Phase 2...